---
title: "AURORA: AI analysis of peripheral immune signatures predicting outcomes in extensive-stage SCLC"
id: "medrxiv-22-aurora-analysing-and-understanding-responses-to-oncological-regimens-with"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-22-aurora-analysing-and-understanding-responses-to-oncological-regimens-with"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.30.26361778v1?rss=1"
published_at: "2026-09-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# AURORA: AI analysis of peripheral immune signatures predicting outcomes in extensive-stage SCLC
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-22-aurora-analysing-and-understanding-responses-to-oncological-regimens-with
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.30.26361778v1?rss=1)
- **Published At:** 2026-09-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Study analysed high-dimensional peripheral blood flow cytometry from 32 patients with stage IV **small-cell lung cancer (SCLC)** treated with carboplatin, etoposide, and atezolizumab. - Samples were taken at baseline (V0) and longitudinally; primary analysis focused on baseline and after two cycles (V1) to identify early predictive biomarkers and limit attrition. - A rigorous machine-learning pipeline employed nested cross-validation, bootstrapping, and permutation testing to evaluate eleven regression and survival models. - Standard regressors failed to generalise (reported R2 < 0 under model-appropriate metrics), whereas censoring-aware **Random Survival Forests (RSF)** produced robust prognostic signatures. - Baseline immune profiles (V0) produced a concordance index (**C-index**) of 0.66 (p = 0.015), and dynamic changes from V0 to V1 (∆V) produced a C-index of 0.65 (p = 0.022). - Absolute measurements at V1 alone did not show a significant prognostic signal (p = 0.445). - Feature importance analysis highlighted normalisation of **Th17** cells and nominated Naive Regulatory T cells and Memory B cells as candidate prognostic components. - Authors frame findings as proof of concept for multivariate liquid-biopsy immune profiling in SCLC and call for confirmation in larger cohorts and integration with tumour-intrinsic data. - Ethical approvals were obtained from the Institutional Review Board of the University Hospital Augsburg (protocol 2020-10, approved 25 April 2020) and written informed consent was collected; data were pseudonymised before computational analysis. - Data from the study are available from the authors upon reasonable request; the article is a medRxiv preprint and not peer-reviewed.
## Clinical Analysis & Structured Key Points
AURORA: Analysing and understanding responses to oncological regimens with artificial intelligence | medRxiv Skip to main content AURORA: Analysing and understanding responses to oncological regimens with artificial intelligence View ORCID Profile Adrian Lebmeier , Tim Lindner , Christian Karl , Thorsten Schöler , Andreas Rank doi: https://doi.org/10.64898/2026.08.30.26361778 Adrian Lebmeier 1 Technical University of Applied Sciences Augsburg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Adrian Lebmeier For correspondence: adrian.lebmeier{at}tha.de Tim Lindner 1 Technical University of Applied Sciences Augsburg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Christian Karl 1 Technical University of Applied Sciences Augsburg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Thorsten Schöler 1 Technical University of Applied Sciences Augsburg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Andreas Rank 2 University Hospital Augsburg Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: Immunochemotherapy (ICT) is considered standard in regards to care for small-cell lung cancer (SCLC) in extensive stages, yet reliable biomarkers for treatment response remain elusive. While previous univariate analyses suggest specific peripheral lymphocyte subsets correlate with survival, the systemic immune response involves complex, multivariate interactions that require advanced analytical approaches. Methods: This paper analysed high-dimensional flow cytometry data from 32 patients with stage IV SCLC treated with carboplatin, etoposide, and atezolizumab. Peripheral blood was analysed at baseline (V0) and longitudinally during treatment. To identify potential early predictive biomarkers and mitigate sample attrition in later cycles, we focused on baseline and measurements after two cycles of ICT (V1). We employed a rigorous machine learning framework utilising nested cross-validation, bootstrapping, and permutation-based statistical testing to evaluate eleven different regression and survival models. Results: Under model-appropriate metrics, regressors did not generalise (R2 <0); conversely, censoring-aware Random Survival Forests (RSF) successfully extracted robust prognostic signatures. Baseline immune profiles (V0) achieved a concordance index (C-index) of 0.66 (p= 0.015), while dynamic changes from V0 to V1 (∆V) achieved a C-index of 0.65 (p= 0.022). Crucially, absolute values measured after two cycles of ICT (V1) yielded no significant signal (p= 0.445). Feature importance analysis confirmed the prognostic value of Th17 normalisation and identified Naive Regulatory T cells and Memory B cells as candidate components. Conclusion: Machine learning validation confirms a predictive signal in the peripheral immune profile of SCLC patients. Early dynamic shifts in the balance between regulatory and effector immune arms are associated with prognosis, contrasting with the lack of signal in absolute counts after two cycles of ICT. These findings establish a proof of concept for multivariate liquid biopsy immune profiling, warranting confirmation in larger cohorts and highlighting the necessity of integrating systemic and tumour-intrinsic data. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of the University Hospital Augsburg, Germany (protocol code 2020-10, approved 25th April 2020). Written informed consent was obtained from all patients and healthy control participants involved in this study. The data were accessed for research purposes between 22 April 2025 and 19 January 2026. During data collection and extraction, authors affiliated with the University Hospital Augsburg (Rank, A.) had access to information that could identify individual participants. The data were pseudonymised before being transferred to the computational authors, who had no access to identifying participant information. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted September 02, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following AURORA: Analysing and understanding responses to oncological regimens with artificial intelligence Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share AURORA: Analysing and understanding responses to oncological regimens with artificial intelligence Adrian Lebmeier , Tim Lindner , Christian Karl , Thorsten Schöler , Andreas Rank medRxiv 2026.08.30.26361778; doi: https://doi.org/10.64898/2026.08.30.26361778 Share This Article: Copy Citation Tools AURORA: Analysing and understanding responses to oncological regimens with artificial intelligence Adrian Lebmeier , Tim Lindner , Christian Karl , Thorsten Schöler , Andreas Rank medRxiv 2026.08.30.26361778; doi: https://doi.org/10.64898/2026.08.30.26361778 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (614) Allergy and Immunology (896) Anesthesia (326) Cardiovascular Medicine (4769) Dentistry and Oral Medicine (474) Dermatology (407) Emergency Medicine (643) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1614) Epidemiology (15834) Forensic Medicine (32) Gastroenterology (1194) Genetic and Genomic Medicine (6983) Geriatric Medicine (727) Health Economics (1057) Health Informatics (4982) Health Policy (1426) Health Systems and Quality Improvement (1736) Hematology (581) HIV/AIDS (1335) Infectious Diseases (except HIV/AIDS) (16243) Intensive Care and Critical Care Medicine (1161) Medical Education (663) Medical Ethics (151) Nephrology (720) Neurology (7193) Nursing (363) Nutrition (1074) Obstetrics and Gynecology (1231) Occupational and Environmental Health (1001) Oncology (3573) Ophthalmology (1036) Orthopedics (393) Otolaryngology (446) Pain Medicine (466) Palliative Medicine (139) Pathology (704) Pediatrics (1772) Pharmacology and Therapeutics (733) Primary Care Research (759) Psychiatry and Clinical Psychology (5832) Public and Global Health (9690) Radiology and Imaging (2387) Rehabilitation Medicine and Physical Therapy (1432) Respiratory Medicine (1239) Rheumatology (633) Sexual and Reproductive Health (766) Sports Medicine (576) Surgery (766) Toxicology (107) Transplantation (302) Urology (286)
## Related Clinical Research

- [No OS Benefit from Adding Chemotherapy to Immunotherapy in PD-L1 TPS ≥50% Advanced NSCLC: Agent-St](https://medichelpline.com/clinical-feed/medrxiv-1-no-overall-survival-benefit-with-adding-chemotherapy-to-immunotherapy-in-pd-l1.md)
- [Informational Video Nudge Boosts Lung Cancer Screening Orders in Randomized Feasibility Trial](https://medichelpline.com/clinical-feed/medrxiv-5-increasing-lung-cancer-screening-participation-using-an-informational-video.md)
- [Moderna and Merck’s cancer vaccine algorithm: what’s known and why it matters](https://medichelpline.com/clinical-feed/stat-news-1-what-s-in-merck-and-moderna-s-cancer-vaccine-algorithm.md)
- [Paclitaxel formulations and reported risk of macular oedema: real‑world JADER analysis](https://medichelpline.com/clinical-feed/plos-one-2-real-world-analysis-of-macular-oedema-associated-with-paclitaxel-formulations.md)
- [Exosome-mediated siRNA delivery in cancer: loading strategies, targeting approaches, and therapeut](https://medichelpline.com/clinical-feed/pubmed-42545436.md) (DOI: 10.1007/s40199-026-00631-z)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.